Skip to content

AMYLIN PHARMACEUTICALS INC

CIK 0000881464

← back to feed
Revenue (TTM)
$656.04M
−2.7% YoY Q1 Jan 2013
Net Income (TTM)
−$217.87M
−3,397.1% YoY Q1 Jan 2013
EPS Diluted (TTM)
−$1.29
+19.7% YoY Q1 Jan 2013
Gross Margin
22.6%
Q1 Jan 2013
Operating Margin
-17.8%
Q1 Jan 2013
Net Margin
-33.2%
Q1 Jan 2013
Free Cash Flow (TTM)
$33.85M
Q1 Jan 2013
Cash
$99.86M
Q1 Jan 2013
Total Debt
$94.39M
Q1 Jan 2013
Shares Outstanding
164.28M sh
Q1 Jan 2013

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings